Maeve O'Meara - 12 Jan 2022 Form 4 Insider Report for CASTLIGHT HEALTH, INC.

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
18 Feb 2022, 13:10:05 UTC
Prior SEC filing
18 Nov 2021
Next SEC filing
23 Mar 2022
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Mary Ahern, as attorney-in-fact

Key filing fact

Maeve O'Meara filed Form 4 for CASTLIGHT HEALTH, INC. on 18 Feb 2022.

Key facts

  • This page summarizes Maeve O'Meara's Form 4 filing for CASTLIGHT HEALTH, INC..
  • 14 reported transactions and 13 derivative rows are listed below.
  • Accepted by SEC: 18 Feb 2022, 13:10.

Change

  • Previous filing in this sequence was filed on 18 Nov 2021.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CSLT transaction

Class B Common Stock

Disposed to Issuer

Transaction value
Shares
-1,625,989
Change %
-100%
Price
Shares after
0
Date
17 Feb 2022
Ownership
Direct
Footnotes
F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CSLT transaction Derivative

Restricted Stock Units (RSU)

Award

Transaction value
$0
Shares
+397,500
Change %
Price
$0.000000
Shares after
397,500
Date
12 Jan 2022
Ownership
Direct
Underlying class
Class B Common Stock
Underlying amount
397,500
Exercise price
Footnotes
F2, F3
CSLT transaction Derivative

Restricted Stock Units (RSU)

Disposed to Issuer

Transaction value
Shares
-12,500
Change %
-100%
Price
Shares after
0
Date
17 Feb 2022
Ownership
Direct
Underlying class
Class B Common Stock
Underlying amount
12,500
Exercise price
Footnotes
F2, F4, F5
CSLT transaction Derivative

Restricted Stock Units (RSU)

Disposed to Issuer

Transaction value
Shares
-25,000
Change %
-100%
Price
Shares after
0
Date
17 Feb 2022
Ownership
Direct
Underlying class
Class B Common Stock
Underlying amount
25,000
Exercise price
Footnotes
F2, F5, F6
CSLT transaction Derivative

Restricted Stock Units (RSU)

Disposed to Issuer

Transaction value
Shares
-115,313
Change %
-100%
Price
Shares after
0
Date
17 Feb 2022
Ownership
Direct
Underlying class
Class B Common Stock
Underlying amount
115,313
Exercise price
Footnotes
F2, F5, F7
CSLT transaction Derivative

Restricted Stock Units (RSU)

Disposed to Issuer

Transaction value
Shares
-301,725
Change %
-100%
Price
Shares after
0
Date
17 Feb 2022
Ownership
Direct
Underlying class
Class B Common Stock
Underlying amount
301,725
Exercise price
Footnotes
F2, F5, F8
CSLT transaction Derivative

Restricted Stock Units (RSU)

Disposed to Issuer

Transaction value
Shares
-558,000
Change %
-100%
Price
Shares after
0
Date
17 Feb 2022
Ownership
Direct
Underlying class
Class B Common Stock
Underlying amount
558,000
Exercise price
Footnotes
F2, F5, F9
CSLT transaction Derivative

Restricted Stock Units (RSU)

Disposed to Issuer

Transaction value
Shares
-430,625
Change %
-100%
Price
Shares after
0
Date
17 Feb 2022
Ownership
Direct
Underlying class
Class B Common Stock
Underlying amount
430,625
Exercise price
Footnotes
F2, F5, F10
CSLT transaction Derivative

Restricted Stock Units (RSU)

Disposed to Issuer

Transaction value
Shares
-397,500
Change %
-100%
Price
Shares after
0
Date
17 Feb 2022
Ownership
Direct
Underlying class
Class B Common Stock
Underlying amount
397,500
Exercise price
Footnotes
F2, F3, F5
CSLT transaction Derivative

Employee Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares
-9,000
Change %
-100%
Price
Shares after
0
Date
17 Feb 2022
Ownership
Direct
Underlying class
Class A Common Stock
Underlying amount
9,000
Exercise price
$1.09
Footnotes
F11, F12, F13, F14
CSLT transaction Derivative

Employee Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares
-7,500
Change %
-100%
Price
Shares after
0
Date
17 Feb 2022
Ownership
Direct
Underlying class
Class A Common Stock
Underlying amount
7,500
Exercise price
$1.12
Footnotes
F11, F12, F13, F14
CSLT transaction Derivative

Employee Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares
-20,000
Change %
-100%
Price
Shares after
0
Date
17 Feb 2022
Ownership
Direct
Underlying class
Class A Common Stock
Underlying amount
20,000
Exercise price
$2.35
Footnotes
F11, F12, F13, F15
CSLT transaction Derivative

Employee Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares
-155,000
Change %
-100%
Price
Shares after
0
Date
17 Feb 2022
Ownership
Direct
Underlying class
Class B Common Stock
Underlying amount
155,000
Exercise price
$2.99
Footnotes
F11, F15
CSLT transaction Derivative

Employee Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares
-331,000
Change %
-100%
Price
Shares after
0
Date
17 Feb 2022
Ownership
Direct
Underlying class
Class B Common Stock
Underlying amount
331,000
Exercise price
$1.01
Footnotes
F16, F17, F18
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Maeve O'Meara is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 18 footnotes

Footnote F1

Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated January 4, 2022, by and among the Issuer, Vera Whole Health, Inc. ("Vera Health"), and Carbon Merger Sub, Inc. (the "Merger Sub"), the Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger (the "Surviving Corporation"), as a wholly owned subsidiary of Vera Health, effective as of February 17, 2022 (the "Effective Time"). Pursuant to the Merger Agreement, each share of the Issuer's Class A common stock and Class B common stock was exchanged for $2.05 in cash (the "Merger Consideration") at the Effective Time.

Footnote F2

Each RSU represents a contingent right to receive one (1) share of the Class B Common Stock upon settlement for no consideration.

Footnote F3

1/3 of the RSUs vested on February 16, 2022 and the remainder will vest quarterly over two years in equal installments, subject to the continuing service of the Reporting Person on each vesting date.

Footnote F4

1/16th of the RSUs vested on February 16, 2018, and the remainder will vest 1/16th quarterly in equal installments, subject to the continuing service of the Reporting Person on each vesting date.

Footnote F5

Pursuant to the Merger Agreement, any RSUs that were unvested at the Effective Time were cancelled and converted at or immediately prior to the Effective Time into the right to receive an amount in cash, without interest, equal to the product of (a) the Merger Consideration multiplied by (b) the total number of unvested shares subject to the RSUs (the "RSU Consideration"). The payment of the RSU Consideration will be subject to vesting in accordance with the vesting schedule applicable to such unvested RSUs immediately prior to Effective Time, subject to the Reporting Person remaining employed by or otherwise in service to the Surviving Corporation on each applicable vesting date.

Footnote F6

1/16th of the RSUs vested on August 16, 2018, and the remainder will vest 1/16th quarterly in equal installments, subject to the continuing service of the Reporting Person on each vesting date.

Footnote F7

1/16th of the RSUs vested on May 16, 2019, and the remainder will vest 1/16th quarterly in equal installments, subject to the continuing service of the Reporting Person on each vesting date.

Footnote F8

1/16th of the RSUs vested on November 16, 2019, and the remainder will vest 1/16th quarterly in equal installments, subject to the continuing service of the Reporting Person on each vesting date.

Footnote F9

1/16th of the RSUs vested on May 16, 2020, and the remainder will vest 1/16th quarterly in equal installments, subject to the continuing service of the Reporting Person on each vesting date.

Footnote F10

1/16th of the RSUs vested on May 16, 2021, and the remainder will vest 1/16th quarterly in equal installments, subject to the continuing service of the Reporting Person on each vesting date.

Footnote F11

The stock option is fully vested and immediately exercisable.

Footnote F12

Each share of Class A Common Stock is convertible at any time at the option of the holder into one (1) share of Class B Common Stock. In addition, each share of Class A Common Stock will convert automatically into one (1) share of Class B Common Stock upon the transfer, whether or not for value, to any transferee who is not a "Permitted Transferee", as defined in the Issuer's Restated Certificate of Incorporation in effect immediately prior to the Effective Time. The shares of Class A Common Stock have no expiration date.

Footnote F13

Each share of Class A Common Stock converted into one (1) share of Class B Common Stock at the Effective Time.

Footnote F14

Pursuant to the Merger Agreement, the option was cancelled and converted at or immediately prior to the Effective Time into a cash payment equal to the product of (a) the aggregate number of underlying shares multiplied by (b) the excess of the Merger Consideration over the applicable per share exercise price of the option.

Footnote F15

The option exercise price is equal to or exceeds the Merger Consideration and therefore the option was automatically cancelled without consideration immediately prior to the Effective Time.

Footnote F16

The option vested as to 1/5th of the total number of shares on March 3, 2021, and thereafter vests as to 1/36th monthly over three years in equal installments, subject to the continuing service of the Reporting Person on each vesting date.

Footnote F17

Pursuant to the Merger Agreement, to the extent vested, the option was cancelled and converted at or immediately prior to the Effective Time into the right to receive a cash payment equal to the product of (a) the aggregate number of underlying shares multiplied by (b) the excess of the Merger Consideration over the applicable per share exercise price of the option. To the extent unvested, the option was cancelled and converted at or immediately prior to the Effective Time into the right to receive a cash replacement amount equal to the product of (a) the aggregate number of underlying shares multiplied by (b) the excess of the Merger Consideration over the applicable per share exercise price of the option cash equivalent award valued based on the excess of the Merger Consideration over the option exercise price (the "Option Consideration"). [continued in fn 18].

Footnote F18

[cont. from fn. 17] The payment of the Option Consideration will be subject to vesting in accordance with the vesting schedule applicable to the unvested portion of the option immediately prior to the Effective Time, subject to the Reporting Person remaining employed by or otherwise in service to the Surviving Corporation on each applicable vesting date.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .